Peer-reviewed veterinary case report
Early blood test to detect gut side effects in dogs on toceranib
By Kovac, Rachel L et al.·Published in Journal of veterinary internal medicine·2018·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib.
- Species:
- dog
Plain-English summary
A group of dogs with mast cell tumors (MCT) receiving a cancer treatment called toceranib were monitored for signs of gastrointestinal (GI) problems. Researchers measured a specific protein in their blood, hoping it would indicate early signs of GI toxicosis, which can occur with this medication. However, the levels of this protein did not reliably predict when the dogs would develop GI issues. Ultimately, the study found that this blood test was not helpful for detecting early GI toxicosis in dogs treated with toceranib.
People also search for: dog cancer treatment side effects · mast cell tumor dog symptoms · toceranib GI problems in dogs
Abstract
BACKGROUND: No biomarkers for the early detection of gastrointestinal (GI) toxicosis secondary to antineoplastic treatment are recognized in veterinary medicine. Toceranib causes GI toxicosis in dogs. HYPOTHESIS/OBJECTIVE: To assess if changes in plasma cytokeratin 18 (CK18) concentration, measured in dogs being treated with toceranib phosphate, can predict the onset of GI toxicosis. We hypothesize that an increase in CK18 concentrations will be detected before the development of GI toxicosis in dogs treated with toceranib phosphate. ANIMALS: Twenty healthy client-owned dogs and 25 client-owned dogs with surgically excised mast cell tumor (MCT). METHODS: Prospective cohort study. Dogs were treated with toceranib (2.75 mg/kg PO q48h). Plasma was collected weekly for 4 weeks. Plasma CK18 concentration was measured on days 0, 7, 14, 21, and 28. vascular endothelial growth factor was measured on days 0 and 28. RESULTS: Mean plasma CK18 concentration on day 0 in dogs with MCT was not significantly different than healthy controls (313.5 ± 592.8 pg/mL, 119.7 ± 76.9 pg/mL, mean ± SD P = 0.27). Mean plasma CK18 concentration decreased by 98.69 pg/mL from day 0 to day 28 (P < 0.001). Plasma CK18 concentration was not a significant predictor of the development of signs of GI toxicosis. CONCLUSIONS AND CLINICAL IMPORTANCE: Plasma CK18 concentration was not a clinically useful biomarker for the early detection of GI toxicosis secondary to toceranib administration in dogs with MCTs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30353992/